,trial_id,trial_status,comp_date,last_updated,emails,results
0,RPCEC00000306,Recruiting,15/07/2020,07/07/2020,"['zurina.cinza@cigb.edu.cu', '-']",No procede
1,RPCEC00000307,Recruiting,30/07/2020,09/07/2020,"['-', 'iraldo.bello@cigb.edu.cu']","1. Channappanavar, R., et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. The Journal of clinical investigation 130, 3625-3639, 312 (2019).
2. Farbod Shahabi nezhad, et al. Therapeutic approaches for COVID-19 based on the dynamics of interferon mediated immune responses. Preprints (www.preprints.org)
3. Yoshikawa T, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS One. 2010;5(1):e8729.
4. Channappanavar R, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625–39.
5. Sainz B, et al. -beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology [Internet]. 2004 Nov 10 
6. García-García I , et al. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co–formulated interferons alpha-2b and gamma in healthy male volunteers. BMC Pharmacol Toxicol 2016;17:58 ."
2,RPCEC00000308,Pending,09/06/2020,13/07/2020,"['hugo.nodarse@cigb.edu.cu', 'carglez@infomed.sld.cu']",No procede
3,RPCEC00000309,Recruiting,15/01/2021,01/03/2021,"['ivan_delgado_enciso@ucol.mx \n\nivancoliman@hotmail.com', 'dr_juanpaz@hotmail.com', 'medicina@ucol.mx; fespin@ucol.mx']","1.- Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. Epub ahead of print 2020. DOI: 10.1148/radiol.2020200642.
2.- Adhikari SP, Meng S, Wu Y, et al. A literature review of 2019 Novel Coronavirus during the early outbreak period: Epidemiology, causes, clinical manifestation and diagnosis, prevention and control. Infect Dis Poverty 2020; 9: 1–12.
3.- Nguyen T, Duong Bang D, Wolff A. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines 2020; 11: 1–7
4.- Poudel A, Meng S, et al. Epidemiology, causes, clinical manifestations and diagnosis, prevention and control coronavirus disease (COV-19) during the early outbreak period: a scoping review. Infectous disease of Poverty. 2020; 9:29. 1-12
5.- Yuen K-S, Ye Z-W, Fung S-Y, et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40.
  Huang C,  Wang Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, Chine, Lancet 2020; 395: 497–50
6.- Paz García J, Trejo Amado R, Gómez Santana JJ, Andrade Monroy C. Nuevo enfoque del tratamiento de la neuralgia trigeminal típica: Estudio multicéntrico. Revista Mexicana de Cirugía Bucal y Maxilofacial 2013;9 (3): 102-108"
4,RPCEC00000310,Recruiting,30/06/2021,14/07/2020,"['mcarmen.reyes@biocen.cu', 'liliamrodriguez@infomed.sld.cu', 'cited@infomed.sld.cu']","1.	Saavedra D, Fuertesb SA, Suárez GM,  González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp  Geront  2019; 124: 110633. Disponible en : https://doi.org/10.1016/j.exger.2019.110633
2.	Rodríguez Martín RR Biomodulina T. Monografía farmacológica. Disponible en: https://studylib.es/doc/110467/biomodulina-t
3.	Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Current opinion in immunology. 2011 Aug;23(4):543-8.
4.	Pawelec G. T-cell immunity in the aging human. Haematologica. 2014 May;99(5):795-7.
5.	Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med 2020. https://doi.org/10.1007/s00134-020-05991-x
6.	Thevarajan, I., Nguyen, T.H.O., Koutsakos, M. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med (2020). Doi: 10.1038/s41591-020-0819-2"
5,RPCEC00000311,Recruiting,31/07/2020,13/08/2020,"['taniac@cim.sld.cu', 'daniel@ipk.sld.cu', 'mayra@cim.sld.cu']","1. Rodríguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernández IM, Hernández MV, Martinez JP, Hernández X, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012; 2:204-11.
2.Tormo BR, García CA, Chong A, Ochoa C, Faxas ME, Sagaró B, Biberfeld P. Immunohistopatology of cutaneous T-cell lymphomas treated with Tepic ior t1 (anti-CD6) monoclonal antibody. Biotecnología Aplicada 11: 20-24, 1994.
•	Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J. CD6-ligand interactions: a paradigm for SRCR domain function? Immunol. Today 1997; 18:498-504. 
•	Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, Bajorath J. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997, 36:2637-2641.
•	Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995, 81:2213-20.
•	Gimferrer, I. et al. Relevance of CD6-mediated interactions in T cell activation and proliferation. J. Immunol 2004; 173: 2262–2270.
•	Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986; 36: 777-784.
•	Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology1988; 38: 42-47.
•	Ibanez A, Sarrias MR, Farnos M Gimferrer I, Serra-Pagès C, Vives J, Lozano F. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol 2006, 177:1152-1159.
•	Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Strom TB, Tilney NL. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 1983; 36: 620-626.
•	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16. pii: S0140-6736(20)30628.
•	Nair P, Melarkode R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clinical and Experimental Immunology 2010, 162:116-130.
•	Rasmussen RA, Counts SL, Daley JF, Schlossman SF. Isolation and characterization of CD6- T cells from peripheral blood. J. Immunol 1994; 152:527-536.
•	Reinherz, E. L., Geha, R., Rappeport, J. M., Wilson, M. Penta, A. C., Hussey, R. E., Fitzgerald, K. A., Daley, J. F., Levine, H., Rosen, E S. and Schlossman, S. F., Proc. Natl. Acad. Sci. USA 1982. 79: 6047.
•	Sarrias, M. R., J. Grønlund, O. Padilla, J. Madsen, U. Holmskov, and F. Lozano. The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit. Rev. Immunol 2004; 24: 1–37. 
•	Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int. Immunol 2002; 14: 585-597.
•	Singer, N. G., B. C. Richardson, D. Powers, F. Hooper, F. Lialios, J. Endres, C. M. Bott, and D. A. Fox. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 1996; 88:537.
•	Whitney GS, Starling GC, Bowen MA, Modrell B, Siadak AW, Aruffo A. The membrane-proximal scavenger receptor cysteinerich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J Biol Chem 1995, 270:18187-18190.
•	Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006; 107:3212–3220."
6,RPCEC00000312,Recruiting,31/12/2020,13/08/2020,"['tradicional@msp.sld.cu', 'aibosch@infomed.sld.cu']","1.	Abadie. A. Semiparametric Difference-in-Difference Estimators. Review of Economic Studies. 2005; 72 (1): 1-19: DOI: 10.1111 / 0034-6527.00321.
2.	Bacallao G. Enfoques modernos del sesgo y la causalidad en la investigación epidemiológica. Revista Cubana de Salud Pública. 2012; 38 (5): 686-701.
3.	Bracho G, Varela E, Fernandez R, Ordaz B, Marzoa N, Menendez J, Garcia, Guilling E, et al. Large-scale application in highly-diluted bacteria for Leptospirosis epidemic control. Homeopathy. 2010; 99.156-166. DOI: 10.1016/j.homp.2010.05.009.
4.	Conde Diez S, Viejo Casas A, Garcia Rivero JL, Lopez Caro JC, Ortiz Portal F, Diaz Saez G. Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: Results of an observational, prospective study (EPOXILO). Respiratory Medicine. 2019; 146: 2019: 96–105. DOI: 10.1016/j.rmed.2018.11.011. 
5.	Jong MC, Buskin SL, Ilyenko L, Kholodova I, Burkart J, Weber S, et al. Effectiveness, safety and tolerability of a complex homeopathic medicinal product in the prevention of recurrent acute upper respiratory tract infections in children: a multicenter, open, comparative, randomized, controlled clinical trial. Jong et al. Multidisciplinary Respiratory Medicine. 2016; 11: 19. DOI 10.1186/s40248-016-0056-1. 
6.	Programa Regional de Bioética, Departamento de Sistemas y Servicios de Salud. Orientación ética sobre cuestiones planteadas por la pandemia del nuevo coronavirus (COVID-19). OPS; 2020 [citado abril 20, 2020]. Disponible en: https://www.paho.org/es/documentos/orientacion-etica-sobre-cuestiones-planteadas-por-pandemia-nuevo-coronavirus-covid-19 
7.	Siqueira C, Homsani F, Veiga F, Lyrio C, Mattos H, Passos S, et al. Homeopathic medicines for prevention of influenza and acute respiratory tract infections in children: blind, randomized, placebo‐controlled clinical trial. Homeopathy 2016; 105 (1): 71‐7."
7,RPCEC00000313,Complete,30/04/2020,13/08/2020,"['-        \n\n                    -', 'mcarmen.dominguez@cigb.edu.cu']","1. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic responses in an animal model of adjuvant induced arthritis. 2011. Autoimmunity; 44(6):471-482. MC Domínguez, N. Lorenzo, A. Barberá,Darrasse-Jeze G, MV Hernandez, AM Torres, I Hernandez, R Gil , D Klatzmann  and  G. Padrón. 
2. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+CD25+ T cells from peripheral blood of rheumatoid arthritis patients. Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM and MC Domínguez. International Immunopharmacology 2013;17 (4): 1075-1083.
3. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis. Biotecnología Aplicada 2013;30:153-156. María del C Domínguez, Norailys Lorenzo, Ariana Barberá, Gabriel Padrón et al.
4. A Peptide as Immunomodulator for the Treatment of Juvenile Idiopathic Arthritis. María del Carmen Domínguez, Noraylis Lorenzo and Dolores Cantera. Ann Rheum Dis 2014; 73:130 doi:10.1136/annrheumdis-2014.  
5. APL-1, an altered peptide ligand derived from human heat-shock protein 60, induces selective activation of nTreg which suppress CD4+ effector T cells from rheumatoid arthritis patients. Ariana Barberá, Noraylis Lorenzo, Peter van Kooten, Joel van Roon, Wilco de Jager, Dinorah Prada, Jorge Gómez, Gabriel Padrón, Willem van Eden, Femke Broere and María del Carmen Domínguez-Horta. Cell Stress and Chaperones. 2016; 21:735–744."
8,RPCEC00000314,Recruiting,30/06/2020,21/10/2020,"['erick.martinez@infomed.sld.cu', 'dagarcia@finlay.edu.cu', 'mariaeugenia@ipk.sld.cu']",No procede
9,RPCEC00000315,Recruiting,30/06/2020,21/10/2020,"['puga@infomed.sld.cu', 'dagarcia@finlay.edu.cu', 'vmarsan@infomed.sld.cu']","Cano MdCA. Population aging in Cuba, from the prism of social epidemiology and ethics Anales de la Academia de Ciencias de Cuba. 2016;Vol.6(No.2).
Cohen AA. Complex systems dynamics in aging: new evidence, continuing questions. Biogerontology. 2016 Feb;17(1):205-20.
Fulop T, Larbi A. Biology of aging: Paving the way for healthy aging. Experimental gerontology. 2018 Jul 1;107:1-3.
Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25: 3066.
Chen J. Senescence and functional failure in hematopoietic stem cells. Exp Hematol 2004; 32: 1025.
Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T.  Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans. Seminars in Immunology 24 (2012) 331– 341
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J med 2020. DOI: 10.1056/NEJMoa2002032
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. doi: 10.12932/AP-200220-0772.
respiratory syndrome coronavirus infection. J. Infect. Dis. 192:1355–1361
X. Li, M. Geng, Y. Peng, L. Meng, S. Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharmaceutical Analysis (2020), doi: https://doi.org/10.1016/j.jpha.2020.03.001.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 [e-pub] DOI:10.1001/jama.2020.2648.
X. Li, M. Geng, Y. Peng, L. Meng, S. Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J Pharmaceutical Analysis (2020), doi: https://doi.org/10.1016/j.jpha.2020.03.001.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. doi: 10.12932/AP-200220-0772.
Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA), acceso en https://clinicaltrials.gov/ct2/show/NCT04328441
  Tay MZ, Poh CM, Rénia L, MacAry PA. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28. doi: 10.1038/s41577-020-0311-8."
10,RPCEC00000316,Complete,03/09/2020,30/03/2022,"['mcarmen.reyes@biocen.cu', 'insnef@infomed.sld.cu        \n\n                    nefro@hha.sld.cu', 'scnefro@infomed.sld.cu']","1. Romero N, Pêrez P, Pérez J, Pérez K, Reyes J, Rodríguez A. Causas de enfermedad renal entre los pacientes de una unidad de hemodiálisis. Rev cub urología;2019;8(1). Disponible en: http://revurologia.sld.cu/index.php/rcu/article/view/461/498
 2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease - A stematic Review and Meta-Analysis. PloS One [Internet]. 2016 [cited 04/11/2018]; 11(7). Available from: Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158765
3. Ayodele O. E, Alebiosu C.O Burden of Chronic Kidney Disease:  An International Perspective J. Advan Chron Kid Dis, 2010; 17: 3, 215-224.
4.  Sosa N , Polo RA, Mendez SN, Sosa M. Caracterización de pacientes con enfermedad renal crónica en tratamiento de hemodiálisis. Medisur. 2016;14(4). Disponible en : http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2016000400006
5. Pérez-Oliva DJF, Almaguer LM, Herrera VR, et al. Comportamiento de la Enfermedad Renal Crónica en la Atención Primaria de Salud. Cuba, 2017. Revista Habanera de Ciencias Médicas. 2018;17(6):1009-1021.
6. Almaguer M, Herrera R, Perez-Oliva JF. Epidemia global de enfermedades vasculares crónicas. Un nuevo paradigma y desafio. Rev Hab C. Médicas.2007; 6: 3.
7. Herrera Valdés R, Almaguer López M, Chipi Cabrera JA, Pérez-Oliva Díaz JF, Landrove Rodríguez O, Mármol Sóñora A. Prevalence and incidence of chronic kidney disease in Cuba. Clin Nephrol. 2019 Sep 24. doi: 10.5414/CNP92S111.
8. Chronic Kidney Disease in the Developing Word. An Iceberg Turned Volcano. Editorial MEDICC. 2005; 7(5): 1-2.
9. Enfermedad renal crónica Cuba 2012: registro cubano de nefrología y terapia renal de reemplazo. http://www.infomed.sld.cu/sitios.
10. Cruz Ma A, Furones JA, Medina Y, de la Fuente I,  Pérez L, Díaz Y.  Eventos adversos observados años después del tratamiento con factor de transferencia. Rev Cubana de Salud Pública 2012; 38(4): 502-10."
11,RPCEC00000317,Pending,29/06/2020,14/09/2020,"['idania.baladron@cigb.edu.cu', 'lrosarioc@infomed.sld.cu', 'silvio.perea@cigb.edu.cu']",No procede
12,RPCEC00000318,Recruiting,14/08/2020,14/09/2020,"['daniel@ipk.sld.cu', 'pereda.gonzalez@infomed.sld.cu']","1)	Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May; 109:102433. doi: 10.1016/ j.jaut.2020.102433.
2)	Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Xu W, Wang ZH, Tebbutt SJ,. Kollmann TR, Fish EN. Interferon-α2b treatment for COVID-19. Frontiers Immunol. 2020. 11:1-6 doi: 10.3389/fimmu.2020.01061.
3)	Jean S-S et al., Treatment options for COVID-19: The reality and challenges, Journal of Microbiology, Immunology and Infection, https://doi.org/10.1016/j.jmii.2020.03.034.
4)	Kujawski SA,Wong K, Collins JP, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv. Preprint posted March 9, 2020. doi: 10.1101/2020.03.09.20032896.
5)	Sanders JM; Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review. JAMA. 2020; 323(18):1824-1836. doi:10.1001/jama.2020.6019.
6)	World Health Organization. (‎2020)‎. Clinical management of severe acute respiratory infection when novel coronavirus (‎‎‎‎‎‎2019-nCoV)‎‎‎‎‎‎ infection is suspected: interim guidance, 28 January 2020. World Health Organization. https://apps.who.int/iris/handle/10665/330893.
7)	Qiu T, Liang S, Dabbous M, Wang Y, Han R, Toumi M. Chinese Guidelines Related to Novel Coronavirus Pneumonia. Preprints 2020, 2020040207 (doi: 10.20944/preprints202004.0207.v1). 
8)	Nodarse-Cuni H, Lopez-Saura P. Cuban interferon alpha-2b. Thirty years as an effective and safe drug. Biotecnol Apl, ene.-mar. 2017, vol.34, no.1, p.1211-1217. ISSN 1027-2852.
9)	Infomed, Portal of the Cuban Health Network. (w.d.). Cuban Protocol against COVID 19. Ministry of Public Health. https://instituciones.sld.cu/facultadfinlayalbarran/protocolo-cuba-vs-covid-4-4-2020."
13,RPCEC00000319,Complete,18/06/2020,14/09/2020,"['mcarmen.reyes@biocen.cu', 'viceamcited@infomed.sld.cu', 'cited@infomed.sld.cu']","1. Nations U. Report of the Second World Assembly on Ageing.  United Nations publication http://www.un.org/en/ga/search/view_doc.asp?symbol=A/CONF.197/92002.
 2. Acosta LF. Mejoran los indicadores de salud y crece la esperanza de vida. In: Granma ndp, revisado en revisado en: http://www.granma.cu/todo-salud/2017-12-29/mejoran-los-indicadores-de-salud-y-crece-la-esperanza-de-vida-29-12-2017-00-12-01, editor. La Habana: Granma; 2017.
3.  Cano MdCA. Population aging in Cuba, from the prism of social epidemiology and ethics Anales de la Academia de Ciencias de Cuba. 2016;Vol.6(No.2).
4.  Cohen AA. Complex systems dynamics in aging: new evidence, continuing questions. Biogerontology. 2016 Feb;17(1):205-20.
5.  Fulop T, Larbi A. Biology of aging: Paving the way for healthy aging. Experimental gerontology. 2018 Jul 1;107:1-3.
6.  Pawelec G. T-cell immunity in the aging human. Haematologica. 2014 May;99(5):795-7.
7.  Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discovery medicine. 2011 Jun;11(61):537-50.
8.  Larbi A, Fulop T. From ""truly naive"" to ""exhausted senescent"" T cells: when markers predict functionality. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2014 Jan;85(1):25-35.
9.  Weltevrede M, Eilers R, de Melker HE, van Baarle D. Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: A systematic review. Experimental gerontology. 2016 May;77:87-95.
10. Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Current opinion in immunology. 2011 Aug;23(4):543-8."
14,RPCEC00000320,Pending,23/08/2020,14/09/2020,"['sallende@infomed.sld.cu', 'zullyt.zamora@cnic.edu.cu']","1. León O S, Menéndez S, Merino N, Castillo R, Sam S, Pérez L, Cruz E, Bocci V. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Inflamm. 1998, 7 (4): 289-294
2. León OS, Takon GO, López GC, Serrano EI, García FE.  Gamma Glutamil transferasa, un marcador de la eficacia clínica del ozono médico y su rol patológico en artritis reumatoide y la osteoartritis de rodilla. Revista Cubana de Reumatología. 2020, 22(1):e104.
3. Martinez G, Menendez S, Copello M, Diaz S, Re L. Rectal insufflation are valid way in ozone therapy. Revista Española de Ozonoterapia. 2012. 2(1):233-235.
4. Martínez Y, et al. Efecto del precondicionamiento oxidativo con ozono en el tiempo de sangrado y formación de trombo venoso en un modelo de choque séptico en ratas. Revista CENIC. Ciencias Biológicas, vol. 41, 2010.
5. Martinez-Sanchez G, Al-Dalain SM, Menendez S, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol. 2005 Oct 31;523(1-3):151-61
6. Mendez I y col. Ozonoterapia en el SIDA Rev Cubana Invest Biomed 2005;24(1):69-71
7. Menendez S, et al. Journal of Ozone Therapy, Vol.2, No.3, 2018: 1 / 26
8. Menéndez S, y col. Ozono. Aspectos básicos y aplicaciones clínicas. Editorial CENIC. ISBN 959-7145-06-5. Primera Edición 2008."
15,RPCEC00000321,Recruiting,30/08/2020,14/09/2020,"['verena.muzio@cigb.edu.cu', 'daniel@ipk.sld.cu', 'mcarmen.dominguez@cigb.edu.cu']","1. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic responses in an animal model of adjuvant induced arthritis. 2011. Autoimmunity; 44(6):471-482. MC Domínguez, N. Lorenzo, A. Barberá,Darrasse-Jeze G, MV Hernandez, AM Torres, I Hernandez, R Gil , D Klatzmann and G. Padrón. 
2. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+CD25+ T cells from peripheral blood of rheumatoid arthritis patients. Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM and MC Domínguez. International Immunopharmacology 2013;17 (4): 1075-1083. 
3. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis. Biotecnología Aplicada 2013;30:153-156. María del C Domínguez, Norailys Lorenzo, Ariana Barberá, Gabriel Padrón et al. 
4. A Peptide as Immunomodulator for the Treatment of Juvenile Idiopathic Arthritis. María del Carmen Domínguez, Noraylis Lorenzo and Dolores Cantera. Ann Rheum Dis 2014; 73:130 doi:10.1136/annrheumdis-2014. 
5. APL-1, an altered peptide ligand derived from human heat-shock protein 60, induces selective activation of nTreg which suppress CD4+ effector T cells from rheumatoid arthritis patients. Ariana Barberá, Noraylis Lorenzo, Peter van Kooten, Joel van Roon, Wilco de Jager, Dinorah Prada, Jorge Gómez, Gabriel Padrón, Willem van Eden, Femke Broere and María del Carmen Domínguez-Horta. Cell Stress and Chaperones. 2016; 21:735–744."
16,RPCEC00000322,Recruiting,15/12/2020,14/09/2020,"['ensayosihi@infomed.sld.cu', 'cmabraham@infomed.sld.cu']",No procede
17,RPCEC00000323,Recruiting,12/10/2020,19/08/2020,"['ensayosihi@infomed.sld.cu', 'cmabraham@infomed.sld.cu']",No procede
18,RPCEC00000330,Pending,30/09/2020,05/10/2020,"['hernandez.bernal@cigb.edu.cu', 'eduardoferat@me.com', '-']","1. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic responses in an animal model of adjuvant induced arthritis. 2011. Autoimmunity; 44(6):471-482. MC Domínguez, N. Lorenzo, A. Barberá,Darrasse-Jeze G, MV Hernandez, AM Torres, I Hernandez, R Gil , D Klatzmann and G. Padrón. 
2. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+CD25+ T cells from peripheral blood of rheumatoid arthritis patients. Barberá A, Lorenzo N, Garrido G, Mazola Y, Falcón V, Torres AM and MC Domínguez. International Immunopharmacology 2013;17 (4): 1075-1083. 
3. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis. Biotecnología Aplicada 2013;30:153-156. María del C Domínguez, Norailys Lorenzo, Ariana Barberá, Gabriel Padrón et al. 
4. A Peptide as Immunomodulator for the Treatment of Juvenile Idiopathic Arthritis. María del Carmen Domínguez, Noraylis Lorenzo and Dolores Cantera. Ann Rheum Dis 2014; 73:130 doi:10.1136/annrheumdis-2014. 
5. APL-1, an altered peptide ligand derived from human heat-shock protein 60, induces selective activation of nTreg which suppress CD4+ effector T cells from rheumatoid arthritis patients. Ariana Barberá, Noraylis Lorenzo, Peter van Kooten, Joel van Roon, Wilco de Jager, Dinorah Prada, Jorge Gómez, Gabriel Padrón, Willem van Eden, Femke Broere and María del Carmen Domínguez-Horta. Cell Stress and Chaperones. 2016; 21:735–744."
19,RPCEC00000332,Recruiting,11/01/2021,12/10/2020,"['cenatox@infomed.sld.cu', 'bparedes@finlay.edu.cu', 'mcrodriguez@finlay.edu.cu']","1) World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: h ttps://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 2) Global regulatory workshop on COVID-19 vaccine development. A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission. 3) Refer to WHO Blueprint information: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. As shown, multiple SARS-CoV-2 vaccine candidates use same/similar platforms as for the other vaccines for which there are established WHO guidance. 4) Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW, Bleicker Tobias, Brünink Sebastian, Schneider Julia, Schmidt Marie Luisa, Mulders Daphne GJC, Haagmans Bart L, van der Veer Bas, van den Brink Sharon, Wijsman Lisa, Goderski Gabriel, Romette Jean-Louis, Ellis Joanna, Zambon Maria, Peiris Malik, Goossens Herman, Reusken Chantal, Koopmans Marion PG, Drosten Christian. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. EuroSurveill. 2020; 25 (3) :pii=2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045. 5) Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals. Available on: https://www.who.int/biologicals/vaccines/en/. 6) Guidelines/Recommendations for other vaccines that may share the same/similar platforms as for SARS-CoV-2 vaccine candidates. 7) Centro  para  el  Control  Estatal  de  la  Calidad  de  los  Medicamentos:  Requerimientos  para  la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos autorizados, Regulación No. 45/2007. 8) Revisiones Bb/La crisis del COVID-19 ha proporcionado al ensayo clínico un papel decisivo y es importante conocer en detalle cómo es este proceso. 9) WHO. Eventos adversos posvacunales (EAP): Evaluación de la causalidad.[cited 2012 Dic 13], available from:http://www.who.int/immunization safety/publications/aefi/831. 10) G Jane, S Katrin, H Scott, Jo H Sandra, Heath Paul, H Renald, Hoet B, et al. A local reaction at or near  injection  site:  Case  definition  and  guidelines  for  collection,  analysis,  and  presentation  of immunization  safety  data.  The  Brighton  Collaboration  Local  Reactions Working  Group  for  A  Local Reaction at or near Injection Site. Vaccine 26 (2008) 6800–6813"
20,RPCEC00000334,Recruiting,31/12/2020,23/10/2020,"['mcarmen.reyes@biocen.cu', 'viceamcited@infomed.sld.cu', 'cited@infomed.sld.cu']","1. Saavedra D, Fuertesb SA, Suárez GM, González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Geront 2019; 124: 110633. Disponible en : https://doi.org/10.1016/j.exger.2019.110633 
2. Rodríguez Martín RR Biomodulina T. Monografía farmacológica. Disponible en: https://studylib.es/doc/110467/biomodulina-t
3. Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Current opinion in immunology. 2011 Aug;23(4):543-8. 
4. Pawelec G. T-cell immunity in the aging human. Haematologica. 2014 May;99(5):795-7. 
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med 2020. https://doi.org/10.1007/s00134-020-05991-x 
6. Thevarajan, I., Nguyen, T.H.O., Koutsakos, M. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med (2020). Doi: 10.1038/s41591-020-0819-2"
21,RPCEC00000335,Recruiting,31/12/2020,23/10/2020,"['mcarmen.reyes@biocen.cu', 'liliamrodriguez@infomed.sld.cu', 'cited@infomed.sld.cu']","1. Saavedra D, Fuertesb SA, Suárez GM, González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Geront 2019; 124: 110633. Disponible en : https://doi.org/10.1016
/j.exger.2019.110633 2. Rodríguez Martín RR Biomodulina T. Monografía farmacológica.
Disponible en: https://studylib.es/doc/110467/biomodulina-t 3. Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Current opinion in immunology. 2011 Aug;23(4):543-8. 4. Pawelec G. T-cell immunity in the aging human. Haematologica. 2014 May;99(5):795-7. 5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‑19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med 2020. https://doi.org/10.1007/s00134-020-05991-x 6. Thevarajan, I., Nguyen, T.H.O., Koutsakos, M. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med (2020). Doi: 10.1038/s41591-020-0819-2"
22,RPCEC00000337,Pending,06/11/2020,05/10/2020,"['hernandez.bernal@cigb.edu.cu', 'docenciahfinlay@infomed.sld.cu']",No procede
23,RPCEC00000338,Complete,31/01/2021,18/08/2021,"['cenatox@infomed.sld.cu', 'bparedes@finlay.edu.cu', 'mcrodriguez@finlay.edu.cu']","1) Chan, J.F., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020;395, 514-523. 
2) WHO Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 
3) DRAFT landscape of COVID-19 candidate vaccines. Disponible en: www. https://covid19.who.int/ 
4) Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry. https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders. 
5) World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: h ttps://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 
6) Global regulatory workshop on COVID-19 vaccine development. A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission. 
7) Refer to WHO Blueprint information: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. As shown, multiple SARS-CoV-2 vaccine candidates use same/similar platforms as for the other vaccines for which there are established WHO guidance. 
8)	Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW, Bleicker Tobias, Brünink Sebastian, Schneider Julia, Schmidt Marie Luisa, Mulders Daphne GJC, Haagmans Bart L, van der Veer Bas, van den Brink Sharon, Wijsman Lisa, Goderski Gabriel, Romette Jean-Louis, Ellis Joanna, Zambon Maria, Peiris Malik, Goossens Herman, Reusken Chantal, Koopmans Marion PG, Drosten Christian. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. EuroSurveill. 2020; 25 (3) :pii=2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
 9) Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals. Available on: https://www.who.int/biologicals/vaccines/en/. 
10) Guidelines/Recommendations for other vaccines that may share the same/similar platforms as for SARS-CoV-2 vaccine candidates"
24,RPCEC00000340,Complete,06/01/2021,15/06/2021,"['cenatox@infomed.sld.cu', 'bparedes@finlay.edu.cu', 'mcrodriguez@finlay.edu.cu']","1- World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: h ttps://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 
2- Global regulatory workshop on COVID-19 vaccine development. A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission.
3- Refer to WHO Blueprint information: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. As shown, multiple SARS-CoV-2 vaccine candidates use same/similar platforms as for the other vaccines for which there are established WHO guidance.
4- Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW, Bleicker Tobias, Brünink Sebastian, Schneider Julia, Schmidt Marie Luisa, Mulders Daphne GJC, Haagmans Bart L, van der Veer Bas, van den Brink Sharon, Wijsman Lisa, Goderski Gabriel, Romette Jean-Louis, Ellis Joanna, Zambon Maria, Peiris Malik, Goossens Herman, Reusken Chantal, Koopmans Marion PG, Drosten Christian. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. EuroSurveill. 2020; 25 (3) :pii=2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
5- Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals. Available on: https://www.who.int/biologicals/vaccines/en/.
6- Guidelines/Recommendations for other vaccines that may share the same/similar platforms as for SARS-CoV-2 vaccine candidates
7- Centro  para  el  Control  Estatal  de  la  Calidad  de  los  Medicamentos:  Requerimientos  para  la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos autorizados, Regulación No. 45/2007.
8- Revisiones Bb/La crisis del COVID-19 ha proporcionado al ensayo clínico un papel decisivo y es importante conocer en detalle cómo es este proceso. 
9- WHO. Eventos adversos posvacunales (EAP): Evaluación de la causalidad.[cited 2012 Dic 13], available from:http://www.who.int/immunization safety/publications/aefi/831.
10- G Jane, S Katrin, H Scott, Jo H Sandra, Heath Paul, H Renald, Hoet B, et al. A local reaction at or near  injection  site:  Case  definition  and  guidelines  for  collection,  analysis,  and  presentation  of immunization  safety  data.  The  Brighton  Collaboration  Local  Reactions Working  Group  for  A  Local Reaction at or near Injection Site. Vaccine 26 (2008) 6800–6813"
25,RPCEC00000341,Complete,25/10/2020,28/10/2020,['zullyt.zamora@cnic.cu'],"Akbudak, et al. Investigation of the effects of major ozone autohemotherapy application on erythrocyte deformability and aggregation. Clinical hemorheology and microcirculation, 2019, vol. 71, no 3, p. 365-372.
Artis A S, et al.The effects of colorectally insufflated oxygen-ozone on red blood cell rheology in rabbits. Clin Hemorheol Microcirc. 2010, 45 (2-4): 329-336. doi: 10.3233/CH-2010-1316.
Bette M, et al. Efficiency of tazobactam/piperacilin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2 pneumoperitoneum. Shock. 2006, 1: 26-29 [PubMed].
Bocci  V et al.  Potentiality of Oxygen-Ozonetherapy to Improve the Health of Aging People. Current Aging Science, Volume 3, Number 3, 2010, pp. 177-187(11) 
Bocci V. Oxygen-Ozone Therapy. A critical Evaluation. Dordrecht, The Netherlands: Kluwer Academic Publisher, 2002:121-170 
Bocci V. Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. J Biol Reg Homeos Ag 1997;10(2/3):31-53.                                                         
Bocci V. Ozone. A new medical drug, Ed Spring, 2011
Borrego A, Zamora Z, González R, Romay C, Hernández F, Menéndez S et al. Protection by ozone preconditioning is mediated by antioxidant system in cysplatin induced nephrotoxicity in rats. Mediat Inflamm. 2004, 13 (1): 13-19. 
Burger R.A., A.R. Torres, R.P. Warren, V.D. Caldwell, B.G. Hughes Echinacea-induced cytokine production by human macrophages. Int. J. Immunopharmacol., 19 (1997), pp. 371-379.  
Calunga JL, Paz Y A, Menéndez S, Martínez A, Hernández A. La ozonoterapia en pacientes con enfisema pulmonar. Rev Med. Chile. 2011, 139:439-449.
Calunga JL, Menendez S, Zamora Z. Ozonetheray on rats submitted to subtotal nephrectomy: role of interleukin 6 and antioxiden System.  Revista Cubana de Investigaciones Biomedicas. 2019, 38 (1)"
26,RPCEC00000342,Complete,15/08/2020,21/12/2020,['zullyt.zamora@cnic.cu'],"Martinez G, Menendez S, Copello M, Diaz S, Re L. Rectal insufflation are valid way in ozone therapy. Revista Española de Ozonoterapia. 2012. 2(1):233-235.
Martínez Y, et al. Efecto del precondicionamiento oxidativo con ozono en el tiempo de sangrado y formación de trombo venoso en un modelo de choque séptico en ratas. Revista CENIC. Ciencias Biológicas, vol. 41, 2010.
Martinez-Sanchez G, Al-Dalain SM, Menéndez S, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol. 2005 Oct 31;523(1-3):151-61
Mausouf MN, Tanbouli TT, tayar WI, El-Masry N, Anas W. Ozone therapy in patients with viral hepatitis C a clinical study. In proceeding of European Congress of the European cooperation of Medical Ozone Scieties.pp23-25, 2003. 
McBride R, van Zyl M. and Fielding B.  The Coronavirus Nucleocapsid Is a Multifunctional Protein.  Viruses, 6, 2991-3018, 2014
Mendez I y col. Ozonoterapia en el SIDA Rev Cubana Invest Biomed 2005;24(1):69-71
Menendez S, et al. Journal of Ozone Therapy, Vol.2, No.3, 2018: 1 / 26
Menéndez S, y col. Ozono. Aspectos básicos y aplicaciones clínicas. Editorial CENIC. ISBN 959-7145-06-5. Primera Edición 2008."
27,RPCEC00000344,Complete,18/04/2020,21/12/2020,"['secdircg@infomed.sld.cu', 'taniajapon@gmail.com \n\ntaniavaldes@infomed.sld.cu']","1.	Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS CoV2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
2.	Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol.2005;79(23):14614–21.
3.	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y ,Li Y, Wang X ,Peng Z(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 5. Zou L, Ruan F, HuangM,Liang L, Huang 
4.	H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N EnglJMed 382:1177–1179.https://doi.org/10. 1056/NEJMc2001737
5.	Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43.
6.	Praditya D, Kirchhoff L, Bru¨ning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 2019;10: 912.
7.	Blumenthal M, Goldberg A, Brinckmann J. Eds. Herbal Medicine: Expanded Commission E Monographs. Austin, TX: American Botanical Council; Newton, MA: Integrative Medicine Communications. 2000. 
8.	Chainani-Wu N. Safety and Anti-Inflammatory Activity of Curcumin: A Component of Turmeric (Curcuma longa).The Journal of Alternative and Complementary Medicine. Volume 9, Number 1, 2003, pp. 161–168.
9.	Zorofchian S y cols. A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin. BioMed Research International 2014, 1-12.
10.	Wen C y cols. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus. J. Med. Chem. 2007, 50, 4087-4095"
28,RPCEC00000345,Pending,31/05/2021,27/11/2020,"['zurina.cinza@cigb.edu.cu', 'cenatox@infomed.sld.cu']",No procede
29,RPCEC00000346,Pending,31/05/2021,27/11/2020,"['hernandez.bernal@cigb.edu.cu', '-']",No procede
30,RPCEC00000347,Complete,12/03/2021,28/01/2022,"['bparedes@finlay.edu.cu', 'orlelibre@infomed.sld.cu', 'mcrodriguez@finlay.edu.cu']","1) World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: h ttps://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 
2) Global regulatory workshop on COVID-19 vaccine development. A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission.
3) Refer to WHO Blueprint information: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. As shown, multiple SARS-CoV-2 vaccine candidates use same/similar platforms as for the other vaccines for which there are established WHO guidance.
4) Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW, Bleicker Tobias, Brünink Sebastian, Schneider Julia, Schmidt Marie Luisa, Mulders Daphne GJC, Haagmans Bart L, van der Veer Bas, van den Brink Sharon, Wijsman Lisa, Goderski Gabriel, Romette Jean-Louis, Ellis Joanna, Zambon Maria, Peiris Malik, Goossens Herman, Reusken Chantal, Koopmans Marion PG, Drosten Christian. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. EuroSurveill. 2020; 25 (3) :pii=2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
5) Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals. Available on: https://www.who.int/biologicals/vaccines/en/.
6) Guidelines/Recommendations for other vaccines that may share the same/similar platforms as for SARS-CoV-2 vaccine candidates
7) Centro  para  el  Control  Estatal  de  la  Calidad  de  los  Medicamentos:  Requerimientos  para  la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos autorizados, Regulación No. 45/2007.
8) Revisiones Bb/La crisis del COVID-19 ha proporcionado al ensayo clínico un papel decisivo y es importante conocer en detalle cómo es este proceso. 
9) WHO. Eventos adversos posvacunales (EAP): Evaluación de la causalidad.[cited 2012 Dic 13], available from:http://www.who.int/immunization safety/publications/aefi/831.
10) G Jane, S Katrin, H Scott, Jo H Sandra, Heath Paul, H Renald, Hoet B, et al. A local reaction at or near  injection  site:  Case  definition  and  guidelines  for  collection,  analysis,  and  presentation  of immunization  safety  data.  The  Brighton  Collaboration  Local  Reactions Working  Group  for  A  Local Reaction at or near Injection Site. Vaccine 26 (2008) 6800–6813"
31,RPCEC00000348,Pending,11/07/2021,26/01/2021,"['carmenap@infomed.sld.cu.', 'ichoninor@infomed.sld.cu', 'milycruz890329@gmail.com']","1. M. Extermann, I. Boler, R.R. Reich, G.H. Lyman, R.H. Brown, J. DeFelice, et al.Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score Cancer, 118 (2012), pp. 3377-3386.
2. A. Mislang, L. BiganzoliAdjuvant systemic therapy in older breast cancer women: can we optimize the level of care? Cancers (Basel), 7 (2015), pp. 1191-1214.
3. J. Leone, B.A. Leone, J. LeoneAdjuvant systemic therapy in older women with breast cancer Breast Cancer Targets Ther, 8 (2016), pp. 141-147.
4. A. Brunello, A. Fontana, V. Zafferri, F. Panza, P. Fiduccia, U. Basso, et al.Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients J Cancer Res Clin Oncol, 142 (2016), pp. 1069-1077.
5. S. Jonna, L. Chiang, J. Liu, M.B. Carroll, K. Flood, T.M. WildesGeriatric assessment factors are associated with mortality after hospitalization in older adults with cancer Support Care Cancer, 24 (2016), pp. 4807-4813.
6. S.S. Shachar, H.B. MussInternet tools to enhance breast cancer care NPJ breast cancer, 2 (2016), p. 16011.
7. M. Vallet-Regí, M. Manzano, L. Rodriguez-Mañas, M. Checa López, M. Aapro, L. BalducciManagement of cancer in the older age person: an approach to complex medical decisions Oncologist, 22 (2017), pp. 335-342.
8. T. Koll, M. Pergolotti, H.M. Holmes, H.C. Pieters, G.J. van Londen, Z.A. Marcum, et al.Supportive care in older adults with cancer: across the continuum Curr Oncol Rep, 18 (2016), p. 51.
9. S.G. Mohile, C. Velarde, A. Hurria, A. Magnuson, L. Lowenstein, C. Pandya, et al.Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts J Natl Compr Canc Netw, 13 (2015), pp. 1120-1130.
10. Saavedra D, Fuertesb SA, Suárez GM, González A, Lorenzo-Luaces P, García B, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp  Geront  2019; 124: 110633. Disponible en : https://doi.org/10.1016/j.exger.2019.110633."
32,RPCEC00000349,Complete,13/02/2021,27/04/2021,"['ochoa@finlay.edu.cu', 'bparedes@finlay.edu.cu', '-']","1.	Shi-Lee W, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology. 2020;5:1185-91. 
2.	Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584:353-63. 
3.	Lópea-Pérez GT, Ramírez-Sandoval MLP, Torres-Altamirano MS. Participantes de la respuesta inmunológica ante la infección por SARS-CoV-2. Alergia, Asma e Inmunología Pediátricas. 2020;29(1):5-15. Doi: 10.35366/93321. 
4.	Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Zh. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 2020. Disponible en: https://doi.org/10.1038/S41577-020-00434-6
5.	Wu SL, Mertens AN, Crider YS, Nguyen A, Pokpongkiat NN, Djajadi S, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. Natute Communications.  2020;11:4507. Disponible en: https://doi.org/10.1038/s41467-020-18272-4
6.	Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19. Versión 1.5. La Habana; MINSAP: 2020.
7.	International Society for Infectious Diseases. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International Journal of Infectious Diseases. 2020;94:154-55.
8.	Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv preprint. 2020: doi: 10.1101/2020.06.08.138990.
9.	Brouwer PhJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643-50.
10.	Hotez PJ, Corry DB, Strych U, Bottazzi ME. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nature Reviews Immunology. 2020. Disponible en: https://doi.org/10.1038/S41577-020-0358-6"
33,RPCEC00000350,Complete,21/10/2020,25/01/2021,"['secdircg@infomed.sld.cu', 'taniajapon@gmail.com \n\ntaniavaldes@infomed.sld.cu']","1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS CoV2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
2. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol.2005;79(23):14614–21.
3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y ,Li Y, Wang X ,Peng Z(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 5. Zou L, Ruan F, HuangM,Liang L, Huang
4. H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N EnglJMed 382:1177–1179.https://doi.org/10. 1056/NEJMc2001737
5. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43.
6. Praditya D, Kirchhoff L, Bru¨ning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 2019;10: 912.
7. Blumenthal M, Goldberg A, Brinckmann J. Eds. Herbal Medicine: Expanded Commission E Monographs. Austin, TX: American Botanical Council; Newton, MA: Integrative Medicine Communications. 2000
8. Chainani-Wu N. Safety and Anti-Inflammatory Activity of Curcumin: A Component of Turmeric (Curcuma longa).The Journal of Alternative and Complementary Medicine. Volume 9, Number 1, 2003, pp. 161–168.
9. Zorofchian S y cols. A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin. BioMed Research International 2014, 1-12. 10. Wen C y cols. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus. J. Med. Chem. 2007, 50, 4087-4095"
34,RPCEC00000351,Complete,26/11/2020,25/01/2021,"['secdircg@infomed.sld.cu', 'taniajapon@gmail.com \n\ntaniavaldes@infomed.sld.cu']","1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS CoV2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
2. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol.2005;79(23):14614–21.
3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y ,Li Y, Wang X ,Peng Z(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 5. Zou L, Ruan F, HuangM,Liang L, Huang
4. H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N EnglJMed 382:1177–1179.https://doi.org/10. 1056/NEJMc2001737
5. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43.
6. Praditya D, Kirchhoff L, Bru¨ning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 2019;10: 912.
7. Blumenthal M, Goldberg A, Brinckmann J. Eds. Herbal Medicine: Expanded Commission E Monographs. Austin, TX: American Botanical Council; Newton, MA: Integrative Medicine Communications. 2000
8. Chainani-Wu N. Safety and Anti-Inflammatory Activity of Curcumin: A Component of Turmeric (Curcuma longa).The Journal of Alternative and Complementary Medicine. Volume 9, Number 1, 2003, pp. 161–168.
9. Zorofchian S y cols. A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin. BioMed Research International 2014, 1-12. 10. Wen C y cols. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus. J. Med. Chem. 2007, 50, 4087-4095"
35,RPCEC00000352,Complete,25/11/2020,25/01/2021,"['secdircg@infomed.sld.cu', 'taniajapon@gmail.com \n\ntaniavaldes@infomed.sld.cu']","1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS CoV2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–90.
2. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol.2005;79(23):14614–21.
3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y ,Li Y, Wang X ,Peng Z(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 5. Zou L, Ruan F, HuangM,Liang L, Huang
4. H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N EnglJMed 382:1177–1179.https://doi.org/10. 1056/NEJMc2001737
5. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43.
6. Praditya D, Kirchhoff L, Bru¨ning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective properties of the golden spice curcumin. Front Microbiol. 2019;10: 912.
7. Blumenthal M, Goldberg A, Brinckmann J. Eds. Herbal Medicine: Expanded Commission E Monographs. Austin, TX: American Botanical Council; Newton, MA: Integrative Medicine Communications. 2000
8. Chainani-Wu N. Safety and Anti-Inflammatory Activity of Curcumin: A Component of Turmeric (Curcuma longa).The Journal of Alternative and Complementary Medicine. Volume 9, Number 1, 2003, pp. 161–168.
9. Zorofchian S y cols. A Review on Antibacterial, Antiviral, and Antifungal Activity of Curcumin. BioMed Research International 2014, 1-12. 10. Wen C y cols. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus. J. Med. Chem. 2007, 50, 4087-4095"
36,RPCEC00000353,Pending,30/04/2022,02/03/2021,"['pablo.dias@cigb.edu.cu', 'julio.aguilar@cigb.edu.cu', 'idelsisem@infomed.sld.cu']",No procede
37,RPCEC00000354,Complete,07/11/2021,30/10/2021,"['-', 'mayragc@infomed.sld.cu', 'mcrodriguez@finlay.edu.cu']","1) World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Disponible en: h ttps://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 
2) Global regulatory workshop on COVID-19 vaccine development. A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission. 
3) Refer to WHO Blueprint information: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. As shown, multiple SARS-CoV-2 vaccine candidates use same/similar platforms as for the other vaccines for which there are established WHO guidance. 
4) Corman Victor M, Landt Olfert, Kaiser Marco, Molenkamp Richard, Meijer Adam, Chu Daniel KW, Bleicker Tobias, Brünink Sebastian, Schneider Julia, Schmidt Marie Luisa, Mulders Daphne GJC, Haagmans Bart L, van der Veer Bas, van den Brink Sharon, Wijsman Lisa, Goderski Gabriel, Romette Jean-Louis, Ellis Joanna, Zambon Maria, Peiris Malik, Goossens Herman, Reusken Chantal, Koopmans Marion PG, Drosten Christian. Detection of 2019 novel coronavirus (2019- nCoV) by real-time RT-PCR. EuroSurveill. 2020; 25 (3) :pii=2000045. https://doi.org/10.2807 /1560-7917.ES.2020.25.3.2000045. 
5) Relevant WHO documents for SARS-CoV-2 vaccines and other biologicals. Available on: https://www.who.int/biologicals/vaccines/en/. 
6) Guidelines/Recommendations for other vaccines that may share the same/similar platforms as for SARS-CoV-2 vaccine candidates
7) Centro para el Control Estatal de la Calidad de los Medicamentos: Requerimientos para la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos autorizados, Regulación No. 45/2007.
8) Revisiones Bb/La crisis del COVID-19 ha proporcionado al ensayo clínico un papel decisivo y es importante conocer en detalle cómo es este proceso. 
9) WHO. Eventos adversos posvacunales (EAP): Evaluación de la causalidad.[cited 2012 Dic 13], available from:http://www.who.int/immunization safety/publications/aefi/831. 
10) G Jane, S Katrin, H Scott, Jo H Sandra, Heath Paul, H Renald, Hoet B, et al. A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. The Brighton Collaboration Local Reactions Working Group for A Local Reaction at or near Injection Site. Vaccine 26 (2008) 6800–6813 U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. Silver Spring, MD 20993-0002, May 2020"
38,RPCEC00000356,Pending,12/08/2021,15/03/2021,"['labinfme@infomed.sld.cu', 'aceliac@cencec.sld.cu', 'eduardo.penton@cigb.edu.cu \n\neduardopenton45@gmail.com']",No procede
39,RPCEC00000357,Complete,20/11/2020,22/03/2021,"['ceic.sedesa@gmail.com', 'brendapazmichel@gmail.com', 'prosemed@yahoo.com.mx']","1.- Cabello Guitierrez C, Rosete Olvera DP, Manjarrez Zavala ME. Efecto de una solución electrolizada de superoxidación con pH neutro sobre la infección del virus de influenza A en células MDCK. Revista del Instituto Nacional de Enfermedades Respiratorias, 2009, vol. 22, (4): 280-287
2.- Velazquez-Meza ME, Hernández-Salgado M, Sánchez-Alemán MA . ""Evaluation of the antimicrobial activity of a super oxidized solution in clinical isolates."" Microbial Drug Resistance 2015, vol. 21 (4): 367-372."
40,RPCEC00000359,Complete,25/06/2021,04/04/2022,"['hernandez.bernal@cigb.edu.cu', '-']",No procede
41,RPCEC00000360,Pending,01/08/2022,09/11/2021,"['-', 'mayragc@infomed.sld.cu', 'mcrodriguez@finlay.edu.cu']","1. Design of vaccine efficacy trials to be used during public health emergencies – points of considerations and key principles- www.who.int/blueprint. Ap1-guidelines-online-consultation 
2. WHO Coronavirus Disease (COVID-19) Dashboard (Data last updated: 2021/2/19, 4:18pm CE) Disponible en: https://covid19.who.int/ 
3. Nota informativa sobre la COVID-19 en Cuba: 19 de febrero. Disponible en: http://www.sld.cu/noticia/2021/02/19/nota-informativa-sobre-la-covid-19-en-cuba-19-de-febrero 
4. Martínez-Díaz E, Pérez-Rodríguez R, Herrera-Martínez L, Lage-Dávila A, Castellanos-Serra L. La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19. Anales de la Academia de Ciencias de Cuba [revista en Internet]. 2020 [citado 2021 Feb 19]; 10(2):[aprox. 0 p.]. Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/906 
5. Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodríguez L, Sanchez Ramírez B, et a. SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.02.08.430146 , https://www.biorxiv.org/content/10.1101/2021.02.08.430146v1 
6. Instituto Finlay de Vacunas. SOBERANA 02A. Registro Público Cubano de Ensayos Clínicos Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000340-Sp.
7. Instituto Finlay de Vacunas. SOBERANA 02A. Registro Público Cubano de Ensayos Clínicos Disponible en: https://rpcec.sld.cu/ensayos/ RPCEC00000347-Sp
8. Koh D. Occupational risks for COVID-19 infection. Occupational Medicine. 2020 [acceso: 21/04/2020];70(1):3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107962/ 
9. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J. Med 2020 [acceso: 21/04/2020];382(18):1708-20. Disponible en: https://doi.org/10.1056/NEJMoa2002032 
10. Associació Catalana de Salut Laboral. Criterios para la gestión de personas especialmente vulnerables y trabajadores/as especialmente sensibles frente al SARS – CoV 2 en las empresas de Cataluña en el contexto de pandemia. Arch Prev Riesgos Labor [Internet]. 2020 [citado 11 May 2020];23(2):[aprox. 19 p.]. Disponible en:  https://archivosdeprevencion.eu/index.php/aprl/article/download/51/27"
42,RPCEC00000361,Pending,30/06/2021,26/03/2021,"['hadier@infomed.sld.cu', 'mayra@cim.sld.cu']","1.	E Montero*, G Reyes†, M Guibert‡, O Torres*, N Rodriguez†, J Estrada†, L Torres§, R Perez*, A Hernandez†, A Lage* Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody. Arthritis Res 2002, 4 (suppl 1).
2. Rodriguez PC. Informe de Ensayo Clínico. Ensayo Clínico Fase I: Evaluación de la toxicidad del AcM humanizado itolizumab (anti-CD6) en pacientes con Artritis Reumatode. Centro de Inmunología Molecular Feb, 2007.
3. Rodríguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernández IM, Hernández MV, Martinez JP, Hernández X, et al. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol 2012; 2:204-11.
4. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56: 864–867, 2004.
5. Human retrovirology: HTLV. New York: Raven Press; 1990. p. 32732
6. Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int. Immunol. 14: 585-597, 2002.
7. Aira y cols. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. 
8. Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J. CD6-ligand interactions: a paradigm for SRCR domain function? Immunol. Today 1997; 18:498-504. 
9. Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, Bajorath J. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997, 36:2637-2641.
10. Singer, N. G., B. C. Richardson, D. Powers, F. Hooper, F. Lialios, J. Endres, C. M. Bott, and D. A. Fox. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 1996; 88:537.
11. Whitney GS, Starling GC, Bowen MA, Modrell B, Siadak AW, Aruffo A. The membrane-proximal scavenger receptor cysteinerich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J Biol Chem 1995, 270:18187-18190.
12. Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006; 107:3212–3220."
43,RPCEC00000363,Pending,30/09/2021,08/04/2021,"['sresik@ipk.sld.cu', 'orleliebre@infomed.sld.cu', 'pablo.dias@cigb.edu.cu']","1.	World Health Organization Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news-room/detail/30-01-2020
2.	Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome. 23 de enero de 2020 (citado 7 de febrero de 2020]; disponible en:  http://www.ncbi.nlm.nih.gov/nuccore/MN908947.3
3.	OPS-OMS. Actualización Epidemiológica. Nuevo coronavirus (COVID-19),  feb. 2020 [Consultado: 3 de abril 2020] Disponible en: https://www.paho.org/sites/default/files/2020-02/2020-feb-28-phe-actualizacionepi-covid19.pdf
4.	WHO. Declaración del Comité de Emergencias del Reglamento Sanitario Internacional acerca del brote del nuevo coronavirus (2019-nCoV). 10 de marzo de 2020. (consultado el 13 abril de 2020). https://www.who.int/es/news-room/detail/30-01-2020-emergency committee regarding the outbreak of novel coronavirus (2019-ncov)
5.	Ministerio de Salud Pública. Partes Diarios oficiales de la COVID-19. Disponibles en: https://temas.sld.cu/coronavirus/covid-19/
6.	Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet]. 24 de febrero de 2020 [citado 6 de marzo de 2020];0(0). Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/abstract 
7.	WHO-Coronavirus disease 2019 (COVID-19) Situation Report-121/2020. https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/-covid- 19.pdf. 
8.	Ju B, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bio Rxiv. 2020. doi:10.1101/2020.03.21.990770
9.	Declaración de Helsinki, actualizada en Fortaleza, Brasil 2013 en:  http://www.wma.net/en/30publications/10policies/b3/index.html 
10.	World Health Organization  Adverse Reaction Terminology WHO-ART  Dictionary 2012 
11.	Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification (Second edition). 2018 . 
12.	Brodersen K., Gallusser F., Koehler J., et al. Inferring causal impact using Bayesian Structural Time-Series models. The Annals of Applied Statistics 2015, Vol 9, No 1, 247-274. DOI: 10.1214/14-AOAS788."
44,RPCEC00000366,Complete,14/06/2021,19/11/2021,"['vmarsan@infomed.sld.cu', 'ochoa@finlay.edu.cu', 'ycliment@finlay.edu.cu']","1.	Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Zh. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 2020. Disponible en: https://doi.org/10.1038/S41577-020-00434-6
2.	Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19. Versión 1.5. La Habana; MINSAP: 2020.
3.	International Society for Infectious Diseases. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International Journal of Infectious Diseases. 2020;94:154-55.
4.	Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv preprint. 2020: Disponible en: https://doi.org/10.1101/2020.06.08.138990 
5.	Brouwer PhJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643-50.
6.	Hotez PJ, Corry DB, Strych U, Bottazzi ME. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nature Reviews Immunology. 2020. Disponible en: https://doi.org/10.1038/S41577-020-0358-6.
7.	Shen Ch, Wang Zh, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;27: Disponible en: https://doi.org/10.100/jama.2020.4783  
8.	Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;29. Disponible en: https://doi.org/10.1038/s41586-020-2599-8 
9.	Alturki SO, Alturki-Sawsan O, Connors J, Cusimano G, Kutzler MA, Izmirly AM, Haddad EK. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Frontiers in Immunology. 2020;11: Disponible en: https://doi.org/10.3389/fimmu.2020.01880 
10.	Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C, et al. A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. medRxiv preprint. 2021. Disponible en: https://doi.org/10.1101/2021.02.22.21252091"
45,RPCEC00000369,Pending,31/07/2021,15/06/2021,"['hosjtrigo@infomed.sld.cu        \n\n                    sallende@infomed.sld.cu', 'mayra@cim.sld.u', 'mayra@cim.sld.cu']","1.- Boban, M. (2021). Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract, 75(4), e13868. doi:10.1111/ijcp.13868
2.- Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Mol Oncol, 12(1), 3-20. doi:10.1002/1878-0261.12155
3.- Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med 2020.
4.- Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020; 8: 693.
5.- Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical effects. Cancers. (2011) 3:2014–31. doi: 10.3390/cancers3022014
6.- Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. (2011) 11:373– 82. doi: 10.4161/cbt.11.4.14097
7.- Rengifo CE, Blanco R, Blanco D, Cedeño M, Frómeta M, Calzado ER Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy..J Biomark. 2013;2013:627845
8.- Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, et al. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of egfr-specific t cells in head and neck cancer patients. Front Pharmacol. (2017) 8:382"
46,RPCEC00000374,Complete,07/10/2021,01/04/2022,"['bparedes@finlay.edu.cu', 'direccionjmm@pejm.sld.cu', 'mcrodriguez@finlay.edu.cu']","1.  Chan, J.F., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020;395, 514-523.
2. WHO Coronavirus Disease (COVID-19) Dashboard. Disponible en: https://covid19.who.int/
3. MINSAP. Parte de cierre del día 5 de mayo a las 12 de la noche 2021 [Available from: https://salud.msp.gob.cu/parte de cierre del día 12 de mayo a las 12 de la noche.]
4. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69:635.
5. Leidman E, Duca LM, Omura JD, et al. COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:88.
6. WHO Coronavirus Disease (COVID-19) Dashboard. Disponible en: https://covid19.who.int/
7. WHO Coronavirus disease (COVID-2019) situation reports.  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
8. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. Lancet Infect Dis 2020; 20:633.
9. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. Clin Infect Dis 2020.
10. Leidman E, Duca LM, Omura JD, et al. COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:88"
47,RPCEC00000375,Pending,30/01/2023,06/12/2021,"['soraidac@infomed.sld.cu', 'rafel.surez@infomed.sld.cu']","1. Xie, L., Liu, Y., Xiao, Y., Tian, Q., Fan, B., Zhao, H., Chen, W., 2005. Follow-up Study on Pulmonary Function and Lung Radiographic Changes in Rehabilitating Severe Acute Respiratory Syndrome Patients After Discharge. Chest 127, 2119–2124. doi:10.1378/chest.127.6.2119
2. Hui, D.S., Wong, K.T., Ko, F.W., Tam, L.S., Chan, D.P., Woo, J., Sung, J.J.Y., The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest 2005. 128, 2247–2261.doi:10.1378/chest.128.4.2247
3. Venkataraman T. Frieman, MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis, Antiviral Research en línea 2017 [citado: 31 mar 2021]. Disponible en:
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507769/ 
4. Epstein G, Brook E, Eyal O, Edelstein E, Shitrit D. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib. Am J Physiol Lung Cell Mol Physiol en línea. May 2019 [citado: 31 mar 2021]; 316(6). Disponible en:
https://journals.physiology.org/doi/full/10.1152/ajplung.00526.2018?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org"
48,RPCEC00000376,Pending,30/12/2023,27/12/2021,"['liudmila.castro@infomed.sld.cu        \n\n                    victorj@infomed.sld.cu', 'jsanchezm@infomed.sld.cu']","Cantarelli C, Angeletti A, Cravedi P. Eritropoyetina, una proteína multifacética con actividad inmunomoduladora innata y adaptativa. Soy J Transplant. 2019; 19 (9): 2407-2414.
Feng Q. Más allá de la eritropoyesis: los efectos antiinflamatorios de la eritropoyetina. Cardiovasc Res. 2006 1 de septiembre; 71 (4): 615-7.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, T ao Y, et al. Desregulación de la respuesta inmune en pacientes con COVID-19 en Wuhan, China. Clin Infect Dis.2020 Mar 12; ciaa248.
Maltaneri, Maria E Chamorro, Daniela C Vittori, Alcira B Nesse. Differential Effect of Erythropoietin and Carbamylated Erythropoietin in Erythroid and Endothelial Cells. Blood Res Transfus J. 2018; 2(2): 555583. DOI: 10.19080/OABTJ.2018.02.555583
Kakavas S, Demestiha T, Vasileiou P, Xanthos T. Erythropoetin as a novel agent with pleiotropic effects against acute lung injury. Eur J Clin Pharmacol. 2011;67(1):1–9.
Kimakova P, Solar P, Solarova Z, Komel R, Debeljak N. Erythropoietin and its angiogenic activity. Int J Mol Sci. (2017) 18:1519. doi: 10.3390/ijms18071519
Brines, M.; Grasso, G.; Fiordaliso, F.; Sfacteria, A.; Ghezzi, P.; Fratelli, M.; Latini, R.; Xie, Q. W.; Smart, J.; Su-Rick, C. J.; Pobre, E.; Diaz, D.; Gomez, D.; Hand, C.; Coleman, T.; Cerami, A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. USA 2004, 101, 14907-14912.
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al, for the EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients. A randomized controlled trial. JAMA 2002;288:2827-35.
Ehrenreich H, Weissenborn K, Begemann M, Busch M, Vieta E and Miskowiak KW.   Erythropoietin as candidate for supportive treatment of severe COVID-19. Molecular Medicine 2020;26(58):2-9. Disponible en: https://doi.org/10.1186/s10020-020-00186-y"